The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FGFR3 alterations (FGFRalt) in patients (pts) who develop locally advanced or metastatic urothelial cancer (mUC), and their association with tumor subtype and clinical outcomes in pts treated with erdafitinib (erda) vs. pembrolizumab (pembro).
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; Bavarian Nordic; Bristol-Myers Squibb; G1 Therapeutics; Genentech; Gilead Sciences; Ideeya Biosciences; Immunomedics; Janssen; Loxo; Merck; Mirati Therapeutics; NCCN; Nektar; Seagen; Taiho Pharmaceutical
Research Funding - Basilea (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Nektar (Inst); NIH (Inst)
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Janssen; Loxo/Lilly; Merck KGaA; MSD Oncology; MSD Oncology (Inst); Pfizer (Inst); Pfizer/EMD Serono; Roche; Roche (Inst); Seagen; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Nobuaki Matsubara
Honoraria - Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Lilly; Pfizer; Sanofi; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
 
Se Hoon Park
Honoraria - Merck; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Janssen Oncology
Research Funding - Merck Sharp & Dohme LLC (Inst)
 
Robert A Huddart
Consulting or Advisory Role - Astellas Pharma; Bristol Myers Squibb Foundation; F. Hoffmann LaRoche; Gilead Sciences; Janssen-Cilag; Merck KGaA; Merck Sharp & Dohme; Nektar
Speakers' Bureau - Bristol Myers Squibb Foundation; Merck KGaA
 
Earle F Burgess
Stock and Other Ownership Interests - Becton Dickinson; Exelixis; Gilead Sciences; Macrogenics
Honoraria - Exelixis
Consulting or Advisory Role - Johnson & Johnson
Research Funding - Astellas Pharma; Pfizer
 
Jiarui Zhang
Employment - Janssen
Stock and Other Ownership Interests - JJ Innovative Medicine
 
Neil Beeharry
Employment - Janssen
Stock and Other Ownership Interests - JJ Innovative Medicine
 
Shibu Thomas
Employment - Janssen Research & Development
Leadership - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
Research Funding - Janssen Oncology
Patents, Royalties, Other Intellectual Property - 4 patents (Inst)
Travel, Accommodations, Expenses - Janssen Research & Development
 
Nicole L. Stone
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
 
Kris Deprince
Employment - Janssen
Stock and Other Ownership Interests - JJ Innovative Medicine
 
Spyros Triantos
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
 
Woonyoung Choi
Research Funding - Janssen